ensitrelvir   Click here for help

GtoPdb Ligand ID: 11871

Synonyms: compound 3 [PMID: 35352927] | compound I-0006 [WO2022138987] [2] | S-217622 | S217622 | Xocova®
Approved drug PDB Ligand
ensitrelvir is an approved drug (Japan 2022)
Compound class: Synthetic organic
Comment: Ensitrelvir is a newly proposed INN for an antiviral that was revealed in January 2022, in the COVID special section of Proposed List 126. It was therefore assumed to target SARS-CoV-2, and to be a potential drug for the treatment of patients with SARS-CoV-2 infection (COVID-19). We were able to match this chemical structure to the Shiongi lead compound S-217622, following their preprint disclosure. The Shiongi article was subsequently published in J Med Chem in March 2022 [3]. S-217622 is described as a non-covalent oral Mpro inhibitor, with pharmacokinetics that support once-daily dosing. It was formulated as a 1:1 fumaric acid complex. Molecular dynamics simulation has been used to estimate ensitrelvir's effectiveness against 6 common SARS-CoV-2 variants (Alpha AP.1, Beta B.1.351, Gamma P.1.13, Delta AY.116, Omicron BA.1/2/3/4/5 and Lambda C.37) [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 99.96
Molecular weight 531.11
XLogP 4.25
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cn1cnc(n1)Cn1c(=O)[nH]/c(=N\c2cc3cn(nc3cc2Cl)C)/n(c1=O)Cc1cc(F)c(cc1F)F
Isomeric SMILES Clc1c(cc2cn(nc2c1)C)/N=c/1\[nH]c(=O)n(c(=O)n1Cc1c(cc(c(c1)F)F)F)Cc1nn(cn1)C
InChI InChI=1S/C22H17ClF3N9O2/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24/h3-7,10H,8-9H2,1-2H3,(H,28,29,36)
No information available.
Summary of Clinical Use Click here for help
Ensitrelvir (S-217622) was advanced to Phase 2/3 clinical evaluation in Japan (JRCT ID: jRCT2031210350) [1]. Volunteers are being recruited to Phase 3 study. NCT05305547 aims to enrol 1729 volunteers in a collaboration between Shiongi and the US National Institute of Allergy and Infectious Diseases (NIAID). In November 2022, ensitrelvir (Xocova®) was authorised by the Japanese regulator, under their emergency approval scheme.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05409911 A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants Phase 1 Interventional Shionogi Inc.
NCT05363215 A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants Phase 1 Interventional Shionogi Inc.
NCT05305547 A Study to Compare S-217622 With Placebo in Non-Hospitalized High-Risk Participants With COVID-19 Phase 3 Interventional Shionogi Inc.